Comparison of motor strength and function in patients with duchenne muscular dystrophy with or without steroid therapy;Comparação da força e função motora em pacientes com distrofia muscular de duchenne com ou sem corticoterapia

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 5, 2010, Pages 683-688

  Parreira, Samara Lamounier Santana ^a   Dutra Resende, Maria Bernadete ^a   Zanoteli, Edmar ^a   Carvalho, Mary Souza ^a   Marie, Suely Kazue ^a   Reed, Umbertina Conti ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Duchenne muscular dystrophy; Hammersmith motor ability score; Motor ability; MRC scale; Muscle strength; Steroids

Indexed keywords

DEFLAZACORT; PREDNISOLONE; STEROID;

ARTICLE; CHILD; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MOTOR ACTIVITY; MOTOR PERFORMANCE; MUSCLE STRENGTH; PRESCHOOL CHILD; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION;

EID: 78649528462     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000500002     Document Type: Article

References (22)

1. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53:219-228.
2. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 1987; 238:347-350.
3. Bushby K, Finkel R, Birnkrant DJ. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet [Internet].2009, November 30. Avaliable from: www.thelancet.com/neurology.
4. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
5. Wagner R, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochimica et Biophysica 2007;1772: 229-237.
6. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;1: CD003725.
7. th ENMC International Workshop: planning for an international trial of steroid dosage regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands. Neuromuscul Disord 2007;17:423-428.
8. Angelini C. The role of corticosteroids in muscular dystrophy: a critical ap praisal. Muscle Nerve 2007;36:424-435.
9. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefi ts of defl aza cort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
10. Scott OM, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982;5:291-301.
11. Medical Reseach Concil. Aids to the Investigation of peripheral nerve injuries. London, England: Her Majesty's Stationery Office. 1976.
12. Parreira SLS. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatr 2007;65:245-250.
13. Mendell JR, Moxley RT, Griggs RC. Randomized double-blind six month trial of prednisone in Duchenne muscular dystrophy. N Engl J Med 1989;320:1592-1597.
14. Fenichel GM, Mendel JR, Moxley RT, et al. A comparison of daily and alter nate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579.
15. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne distrophy. Randomized controlled trial of prednisone (18 months) and azathioprine. Neurology 1993; 93:520-527.
16. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
17. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004;14:476-482.
18. Biggar WD, Gingas M, Flebings DL, Harris VA, Steele CA. Deflazacort treatment 18. of Duchenne muscular dystrophy. J Ped 2001;138:45-50.
19. Pradhan S, Ghosh D, Srivastava NK, Mittal B, Pandey CM, Singh U. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulate. J Neurol 2006;253:1309-1316.
20. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
21. Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assesment tool. Dev Med Child Neurol 2006; 48:540-544.
22. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002;12(Suppl 1):S169-S174.